AbbVie
ABBV
3,076 hedge funds and large institutions have $165B invested in AbbVie in 2023 Q2 according to their latest regulatory filings, with 152 funds opening new positions, 1,137 increasing their positions, 1,432 reducing their positions, and 184 closing their positions.
46% more call options, than puts
Call options by funds: $2.74B | Put options by funds: $1.87B
0.32% less ownership
Funds ownership: 69.77% → 69.45% (-0.32%)
2% less funds holding
Funds holding: 3,138 → 3,076 (-62)
16% less capital invested
Capital invested by funds: $197B → $165B (-$31.7B)
17% less first-time investments, than exits
New positions opened: 152 | Existing positions closed: 184
21% less repeat investments, than reductions
Existing positions increased: 1,137 | Existing positions reduced: 1,432
43% less funds holding in top 10
Funds holding in top 10: 303 → 172 (-131)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
+$453M |
| 2 |
Barclays
London,
United Kingdom
|
+$305M |
| 3 |
D.E. Shaw & Co
New York
|
+$225M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$185M |
| 5 |
Two Sigma Investments
New York
|
+$176M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$647M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$465M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$406M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$360M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$291M |
ABBV Hedge Fund Activity: Q2 2023 in Review
3,076 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2023, worth a combined $165B — down 16% from $197B a quarter earlier.
Sellers outnumbered buyers: 184 funds closed out of ABBV and 152 opened new positions — a net loss of 32 holders — while 1,432 trimmed existing stakes and 1,137 added.
The largest buyer was Ontario Teachers' Pension Plan Board, adding an estimated $453M. The largest seller was T. Rowe Price Associates, cutting an estimated $647M.
- 3,076 institutional investors held AbbVie (ABBV) as of Q2 2023, down from 3,138 in Q1 2023.
- Funds reported $165B of AbbVie stock for Q2 2023, down 16% quarter-over-quarter.
- 152 funds opened new AbbVie positions in Q2 2023 and 184 closed out, a net change of -32 holders.
- The largest AbbVie buyer in Q2 2023 was Ontario Teachers' Pension Plan Board, an estimated $453M added.
- The largest AbbVie seller in Q2 2023 was T. Rowe Price Associates, an estimated $647M sold.
Based on aggregated 13F filings for Q2 2023.